Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Trial Profile

Special Drug Use Surveillance of EFIENT Tablet - Prasugrel For Japanese patients with ischemic heart disease in long-term use clinical practice -

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Prasugrel (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Ischaemic heart disorders; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRASFIT-Practice II
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 02 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top